Top Markets
Coin of the day
GeneOne Life Science, Inc. GeneOne Life Science, Inc.

GeneOne Life Science, Inc.

011000
Rankning i aktier #27557
GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul,... GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul, South Korea, was founded in 1976. The company focuses on the innovation and manufacturing of gene-based biomedical products. Its developmental pipeline features several candidates: GLS-1027 is in Phase I for nephropathy and inflammatory conditions, and also in Phase II trials for COVID-19. Similarly, GLS-1200 is being tested in Phase II for both Rhinosinusitis and COVID-19. Other compounds under development include GLS-3000 and GLS-5310 for SARS-CoV-2, GLS-5100 targeting VZV-Shingles, and GLS-5140 for SFTS. The company is also advancing GLS-5300 in Phase II for MERS, GLS-5700 in Phase I for Zika, and GLS-6150 in Phase I for hepatitis C, alongside GLS-6100 which is in a pre-clinical stage for hepatitis C. Additionally, through its subsidiary VGXI, Inc., GeneOne Life Science offers contract manufacturing services for nucleic acid-based products, specifically DNA plasmids and mRNA, under cGMP standards. The company adopted its current name in April 2014, having previously been known as VGX International Inc.
Aktiekurs
$1.85
Senast synkroniserad: 2026-07-27
Marknadsvärde
$32.07M
Förändring (1 dag)
0.00%
Förändring (1 år)
-76.96%
Land
KR
Handel GeneOne Life Science, Inc. (011000)

Kategori

EPS för GeneOne Life Science, Inc. (011000)
EPS per 2026 TTM: 0
Enligt GeneOne Life Science, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för GeneOne Life Science, Inc. från 2026 till 2026
EPS vid slutet av varje år
År EPS Ändra
Inte tillräckligt med data för de angivna datumen.
EPS för liknande företag eller konkurrenter
Företag EPS EPS-differens Land
$17.32 -
US
$-7.98 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH